TegoScience is a leading company in the Korean cell therapeutics market.
-
- 2001
-
- 03 20Established in Daejeon, Korea
- 03Designated as 'High-tech Venture Company'
-
- 2002
-
- 03Moved to facility & head office in Seoul
- 09'Cutigen Research Institute' established
- 09Designated as 'Innovative Technology Company'
- 12 10Holoderm® approved /
Production & sales approval by KFDA
-
- 2003
-
- 04Qualified as GMP facility by KFDA
- 06Kaloderm®, IND approved
- 12Awarded excellence award at Korea Healthcare Technology Fair
-
- 2004
-
- 05First export shipment of Neoderm® to Japan
-
- 2005
-
- 03 21Kaloderm® approved for burns by KFDA
- 09Selected as technological innovation task
- 10Awarded silver medal at Korea Technology Fair
- 11Certified as KT(Korea Technology)
- 12Awarded prime minister’s medal at Korea Healthcare Technology Fair
-
- 2006
-
- 01Certified as HT(Health Technology)
- 041stSpecial Symposium
- 09Cultured keratinocyte registered as cosmetics ingredient
(CTFA, US)
- 12Designated as one of 10 best-new technologies
-
- 2007
-
- 03Worker’s Compensation reimbursement for both
Holoderm® and Kaloderm®
- 04Kaloderm® approved National Health Insurance reimbursement for burns
- 12Holoderm® Phase III clinical study completed after approval
-
- 2008
-
-
- 2010
-
- 06Kaloderm® approved additionally for Diabetic Foot Ulcer
-
- 2012
-
- 02Technology transfer from Yonsei University: 'In vivo Induction
Methods for Migrating Stem Cells to a Target Site'
- 05Begined Neoderm® business for sales, distribution of cells
for research and contract research service
-
- 2014
-
- 11 06IPO: KOSDAQ [191420]
-
- 2015
-
- 02Registered the patent 'Method for inducing in vivo migration
of stem cell'(KR)
- 05 06kaloderm® PMS (for diabetic foot ulcer) approved
- 09Designated as ‘K-Brain Power Company'
- 09TPX-105 [Autologous Cultured Fibroblasts] Phase II,
IND approved
- 10Registered the patent 'Method for inducing in vivo migration
of stem cell'(JP)
- 11Registered the patent 'Method for inducing in vivo migration
of stem cell'(US)
-
- 2016
-
- 02Registered the patent ‘Cell Therapy Preparation Inducing
the Release of Cellular Substances for Tissue Regeneration’(KR)
- 03Incorporated 'Cutigen Laboratories', biotechnology-based
cosmetics company as a subsidiary of Tego Science.
- 03Registered the patent 'Method for inducing in vivo migration
of stem cell'(CN)
- 04Registered the patent 'Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis,
and the cultured skin made therefrom(KR)
- 11Certified as 'Innovative Pharmaceutical Company'
-
- 2017
-
- 01Registered the patent ‘Composition for improving skin
condition comprising chemokines’(ICID)
- 04Entered the cosmeceutical cosmetics business through
subsidiary, Cutigen Laboratories
- 08Registered the patent 'Cosmetic composition in the form of cotton candy'(KR)
- 11Completed new GMP facility and relocated head office
- 12Rosmir® approved by KFDA
-
- 2018
-
- 03TPX-114 Phase III, IND approved
-
- 2019
-
- 03Registered the patent 'Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis,
and the cultured skin made therefrom'(US)
- 07Recertified as 'Innovative Pharmaceutical Company'
- 07Registered the patent 'Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis,
and the cultured skin made therefrom'(JP)
- 09Kaloderm® approved National Health Insurance reimbursement for Diabetic Foot Ulcer
-
- 2020
-
- 03TPX-115 Phase II, IND approved
- 09Registered the patent 'Method for preparing a three-dimensionally cultured skin comprising dermis and epidermis,
and the cultured skin made therefrom'(EU)
-
- 2021
-
- 01Registered the patent 'Cosmetic composition in the form of cotton candy'(JP)
- 01Contracted Kaloderm® sales & marketing with SK Chemicals
- 05Registered the patent ‘Composition for improving skin
condition comprising chemokines’(US)